G
Genoox
A healthcare and technology company on a mission to make clinical genetic sequencing more accessible
About Genoox
Genoox operates in the genomic data analysis market, providing a cloud-based platform that translates complex genetic data into clinical results. The platform is designed to manage the sequencing process from raw genetic data to actionable insights, making it a valuable tool for healthcare professionals and researchers. Genoox serves clients such as hospitals, research institutions, and clinical laboratories, offering them an efficient workflow for data analysis. The business model is subscription-based, with clients paying for access to the platform's premium features, including unlimited sample analysis, storage, and various data processing tools. Genoox generates revenue through these subscriptions and offers a 14-day free trial to attract new users. The platform's key features include multiple variant calling and validation tools, an annotation engine, and automated genotypic and phenotypic correlation. Genoox also provides professional services and support to ensure clients can maximize the platform's capabilities.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2014
- Headquarters
- Palo Alto, United States
- Employees
- 53
- Open positions
- None listed
- Dealroom signal
- 64.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Analytics, Data Analytics, Biotechnology, Medical Research, DNA, Genetics and genomics, Precision Medicine, Genome Engineering
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2025 | $70M | $70M | Qiagen | ↗ |
| SERIES C✓Equity / VC | Aug 2023 | $12M | $48M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Genoox is 110K monthly website visits, up 0% over the last three months. Genoox's team declined 1.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
UpWest Labs
Microsoft for Startups
MassChallenge
Series A5 investors entered at this stage
Glilot Capital Partners
Inimiti
TriVentures
IN Venture
Infinity Medical
Other known investors4 additional known investors
Google for Startups Accelerator
Qiagen
Kobi Samboursky
UpWest
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genoox on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genoox’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.